CBD CLINIC™ products are non‑prescription and intended for use under professional guidance.
*The products are not intended to diagnose, treat, cure, or prevent disease and have not been evaluated by FDA for the treatment of any disease.
Science. Safety. Partnership.
For Accountable Care Organizations (ACOs) that are responsibly implementing optional, Centers for Medicare & Medicaid Services (CMS) approved cannabinoid-based wellness approaches, Charlotte’s Web supports compliance‑focused exploration of federally legal hemp‑derived wellness products, subject to all applicable CMS safeguards and approvals.
Charlotte’s Web aids ACOs and healthcare providers participating in the CMS Innovation Center (CMMI) model test programs, specifically the LEAD, REACH, and Enhancing Oncology (EOM) models.
What We Do
Charlotte’s Web provides CBD Clinic, a carefully curated set of hemp-derived CBD wellness products designed to help support the quality of life for seniors experiencing temporary discomfort due to everyday aches, feelings of anxiety, and sleep disruption.
How We Comply
Our program is built to support alignment with (CMS) requirements applicable to CMS Innovation Center (CMMI) model participants, recognizing that all participation decisions and approvals rest solely with CMS and the participating organization. We help enable ACOs to confidently offer the Substance Access Beneficiary Engagement Incentive (BEI) by providing products that are carefully manufactured and distributed in strict accordance with federal regulatory standards.
Collapsible content
Eligible Hemp Products:
All products are federally legal hemp‑derived products containing no more than 0.3% delta‑9 THC and meeting CMS eligibility criteria, including exclusions for inhalable products, synthetic cannabinoids, and products exceeding CMS‑specified THC thresholds.
Participant Eligibility:
Participants may begin offering the Substance Access BEI in the ACO REACH and EOM Models beginning April 1, 2026. The Substance Access BEI becomes available to eligible LEAD Model participants beginning January 1, 2027, subject to CMS approval.
Under the Substance Access BEI, participating organizations that have elected the BEI and received CMS approval may consult with eligible beneficiaries about the possible use of eligible hemp-derived products, as determined appropriate by a physician and documented through required shared decision-making, including medication review and follow-up planning.
Eligible hemp‑derived products must be furnished directly by a qualified physician affiliated with the participating ACO, consistent with CMS model participation requirements.
Participants that elect to implement the Substance Access BEI may furnish eligible hemp-derived products up to $500 per eligible beneficiary, per year, subject to all applicable CMS model requirements and safeguards. Medicare does not pay for these products, and beneficiaries should not submit Medicare claims for them. To learn more about the Substance Access BEI, visit the CMS BEI website.
As new beneficiary engagement options emerge, patients may have questions about product quality and safety. As an established and trusted CBD brand, Charlotte’s Web supports ACOs with educational resources, quality documentation, and operational support to help ACOs confidently explore cannabinoid-based wellness approaches within CMS Innovation Center models, without influencing physician judgment, beneficiary determination, or CMS approval decisions.
Our mission is simple: Support ACOs in responsibly exploring access to science-informed, hemp-derived wellness products focused on general wellness and quality-of-life considerations.
Why This Matters for ACOs
A New Opportunity to Support Senior Quality of Life
Many seniors experience quality-of-life challenges, such as temporary discomfort due to everyday aches, feelings of anxiety, and sleep disruption, that can impact their quality of life and healthcare utilization.
As research and awareness continue to evolve, cannabinoid-based wellness approaches are increasingly being explored as part of a broader conversation around holistic and patient-centered approaches.
Participation in applicable CMMI REACH and LEAD Model test programs provides an opportunity for ACOs to:
-
Explore innovative beneficiary engagement strategies
-
Support quality-of-life considerations for high-need populations
-
Advance whole-person, value-based care models
CBD Clinic by Charlotte’s Web is designed to help ACOs navigate this opportunity safely, thoughtfully, and in alignment with CMS requirements.
Why Charlotte’s Web
A Standard of Excellence in CBD
For more than a decade, Charlotte’s Web has focused on science, safety, and responsible industry leadership in the hemp-derived wellness space.
-
Science-Informed Approach
Our formulations are supported by an internal research and development team led by Dr. Marcel Bonn-Miller, Chief Scientific Officer, focused on advancing cannabinoid science and product quality. The CBD Clinic by Charlotte’s Web product line was carefully developed to support seniors in areas that matter most to them: everyday comfort, sleep quality, and relaxation.
-
Quality & Safety
CBD Clinic by Charlotte’s Web products are developed to meet applicable federal and state quality and safety standards and are intended to support ACO compliance planning, subject to each organization’s CMS-approved implementation plan. Product quality measures include:
- NSF-certified cGMP production
- Third-party finished goods testing at ISO 17025 certified laboratories
- Testing for potency and contaminants, including heavy metals, mycotoxins, pesticides, and residual solvents
-
Credibility & Responsible Innovation
Charlotte’s Web is a widely recognized hemp-derived CBD brand in the United States and remains committed to responsible innovation, transparency, and quality.
Built for ACO Implementation
More Than a Product — A Supportive Partner
Participation in the REACH and LEAD Model test programs requires thoughtful coordination across clinical, compliance, and operational workflows.
Charlotte’s Web is prepared to support ACOs by offering:
-
Supporting Program Integrity
- Audit-ready quality and product documentation
- Compliance-support resources
- Experience in the regulatory landscape for hemp-derived products
-
Reducing Administrative Burden
- Structured operational workflows
- Provider and staff education resources
- Beneficiary-focused educational support
-
Enabling Scalable Programs
- Pilot-ready implementation models
- Operational guidance for care teams
- Support for population health initiatives
Our goal is to help participating ACOs engage confidently and responsibly within CMS Innovation Center models.
Supporting Senior Quality-of-Life Considerations
Focused on Everyday Wellness Needs
CBC Clinic by Charlotte’s Web is designed to support general wellness and quality-of-life considerations commonly experienced by seniors, including:
-
Pain Management
Everyday aches and pains, including muscle and joint discomfort, are among the most common challenges affecting senior populations and often lead to increased healthcare utilization.
-
Anxiety
Stress and anxiety can influence quality of life, independence, and daily functioning.
-
Enabling Scalable Programs
Sleep disruption is a common concern among older adults and can affect both physical and mental well-being.
Through responsible cannabinoid-based wellness innovation, Charlotte’s Web supports ACOs in exploring new ways to support eligible beneficiaries and help improve their quality of life.
No clinical outcome claims are made, and products referenced are intended solely to support general wellness and quality‑of‑life considerations.
Designed for the CMMI Pilot
Supporting the EOM, REACH & LEAD Models | Substance Access BEI
CBD Clinic by Charlotte’s Web was developed to support ACO participation in applicable CMS Innovation Center model test programs that include the Substance Access Beneficiary Engagement Incentive.
Our approach is aligned with key CMMI principles, including:
- Encouraging innovative care and engagement approaches
- Supporting beneficiary engagement
- Maintaining program integrity and compliance
- Advancing value-based care objectives
We are committed to working collaboratively with ACO leadership, clinicians, and compliance teams, recognizing that all participation decisions and approvals rest solely with CMS and the participating organization.
Our Commitment to ACO Partners
Navigating Innovation Responsibly
Charlotte’s Web understands the importance of implementing beneficiary engagement initiatives responsibly and in alignment with CMS safeguards.
We view our role as a long-term partner to ACOs, supporting:
- Education and awareness
- Regulatory and compliance resources
- Operational readiness
- Responsible, voluntary beneficiary engagement
Participation in the Substance Access BEI must not be marketed to induce beneficiary selection or retention and remains subject to physician determination, beneficiary choice, and CMS model safeguards. CBD Clinic by Charlotte’s Web is not marketed directly to Medicare beneficiaries in connection with the Substance Access BEI and is intended solely for consideration by participating ACOs and their affiliated clinicians.
Partner With Charlotte’s Web
Explore the Opportunity
If your ACO is evaluating whether the Substance Access BEI is right for your organization, our team is available to share information and answer operational or compliance-related questions. Learn how CBD Clinic by Charlotte’s Web can support your organization in responsibly exploring optional Substance Access BEI participation involving hemp-derived CBD wellness products, subject to CMS approval, physician determination, beneficiary choice and all applicable safeguards.
FDA Disclosure: These statements have not been evaluated by the Food and Drug Administration. Products referenced are not intended to diagnose, treat, cure, or prevent any disease. Nothing on this site is intended to replace the independent clinical judgment of healthcare professionals or to constitute medical advice.
CMS Notice: Participation in the Substance Access Beneficiary Engagement Incentive (BEI) is voluntary and subject to CMS approval. CMS does not endorse any product or manufacturer. Medicare does not pay for hemp-derived products furnished under the Substance Access BEI. References to Charlotte’s Web or CBD Clinic are informational only and do not imply CMS endorsement, recommendation, or preference. All dates, eligibility, and operational details are subject to CMS guidance, model participation agreements, and change.